Monoclonal antibodies therapies for ovarian cancer.

Monoclonal antibodies therapies for ovarian cancer.

Item
http://www.wikidata.org/entity/Q38078400
Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model.The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.The potential of sunitinib as a therapy in ovarian cancer.Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas.Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer.Cediranib in ovarian cancer: state of the art and future perspectives.Bevacizumab for the treatment of cervical cancer.CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma
P2860

Monoclonal antibodies therapies for ovarian cancer.

Item
http://www.wikidata.org/entity/Q38078400
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Monoclonal antibodies therapies for ovarian cancer.
@en
type
label
Monoclonal antibodies therapies for ovarian cancer.
@en
prefLabel
Monoclonal antibodies therapies for ovarian cancer.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Monoclonal antibodies therapies for ovarian cancer.
@en
P2093
P2860
P304
P31
P356
10.1517/14712598.2013.767328
P407
P433
P478
P50
P577
P5875
P698
P921